- Home
- TRVI vs QQQX Comparison
TRVI vs QQQX Comparison
Compare TRVI & QQQX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- QQQX
- Stock Information
- Founded
- TRVI 2011
- QQQX 2007
- Country
- TRVI United States
- QQQX United States
- Employees
- TRVI N/A
- QQQX N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- QQQX Finance Companies
- Sector
- TRVI Health Care
- QQQX Finance
- Exchange
- TRVI Nasdaq
- QQQX Nasdaq
- Market Cap
- TRVI 1.4B
- QQQX 1.3B
- IPO Year
- TRVI 2019
- QQQX N/A
- Fundamental
- Price
- TRVI $13.34
- QQQX $27.91
- Analyst Decision
- TRVI Strong Buy
- QQQX
- Analyst Count
- TRVI 11
- QQQX 0
- Target Price
- TRVI $20.59
- QQQX N/A
- AVG Volume (30 Days)
- TRVI 1.8M
- QQQX 127.6K
- Earning Date
- TRVI 11-13-2025
- QQQX 01-01-0001
- Dividend Yield
- TRVI N/A
- QQQX 7.03%
- EPS Growth
- TRVI N/A
- QQQX N/A
- EPS
- TRVI N/A
- QQQX N/A
- Revenue
- TRVI N/A
- QQQX N/A
- Revenue This Year
- TRVI N/A
- QQQX N/A
- Revenue Next Year
- TRVI N/A
- QQQX N/A
- P/E Ratio
- TRVI N/A
- QQQX N/A
- Revenue Growth
- TRVI N/A
- QQQX N/A
- 52 Week Low
- TRVI $2.36
- QQQX $20.27
- 52 Week High
- TRVI $13.73
- QQQX $25.99
- Technical
- Relative Strength Index (RSI)
- TRVI 72.54
- QQQX 54.95
- Support Level
- TRVI $10.46
- QQQX $26.30
- Resistance Level
- TRVI $12.14
- QQQX $27.66
- Average True Range (ATR)
- TRVI 0.79
- QQQX 0.53
- MACD
- TRVI 0.06
- QQQX -0.01
- Stochastic Oscillator
- TRVI 92.05
- QQQX 85.48
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest
Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek an attractive total return with less volatility than the Nasdaq 100 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets in an equity portfolio made up of securities comprising the Nasdaq 100 Index (or securities that have economic characteristics that are similar to those securities comprising the Nasdaq 100 Index) that seeks to substantially replicate price movements of the Nasdaq 100 Index and is designed to support the Fund's option strategy.